Market News

Pioneer Investment Management Has Increased Its Interpublic Group Of Compa (IPG) Stake; Shorts at Cymabay Therapeutics (CBAY) Lowered By 10.94%

Pioneer Investment Management Inc increased Interpublic Group Of Compa (IPG) stake by 6.82% reported in 2017Q3 SEC filing. Pioneer Investment Management Inc acquired 121,944 shares as Interpublic Group Of Compa (IPG)’s stock declined 0.78%. The Pioneer Investment Management Inc holds 1.91 million shares with $39.68M value, up from 1.79M last quarter. Interpublic Group Of Compa now has $8.45B valuation. The stock increased 1.30% or $0.28 during the last trading session, reaching $21.74. About 8.05M shares traded or 29.65% up from the average. The Interpublic Group of Companies, Inc. (NYSE:IPG) has risen 3.01% since January 14, 2017 and is uptrending. It has underperformed by 13.69% the S&P500.

Cymabay Therapeutics Incorporated (NASDAQ:CBAY) had a decrease of 10.94% in short interest. CBAY’s SI was 2.22M shares in January as released by FINRA. Its down 10.94% from 2.49M shares previously. With 493,100 avg volume, 5 days are for Cymabay Therapeutics Incorporated (NASDAQ:CBAY)’s short sellers to cover CBAY’s short positions. The SI to Cymabay Therapeutics Incorporated’s float is 8.89%. The stock increased 0.61% or $0.06 during the last trading session, reaching $9.97. About 314,250 shares traded. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since January 14, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $437.33 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Among 6 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 17 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, January 10 by Oppenheimer. H.C. Wainwright maintained the shares of CBAY in report on Monday, July 17 with “Buy” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, September 19. As per Friday, July 1, the company rating was initiated by Roth Capital. Leerink Swann maintained the stock with “Buy” rating in Tuesday, November 28 report. The company was maintained on Monday, September 11 by Piper Jaffray. The firm has “Buy” rating given on Monday, January 30 by H.C. Wainwright. The rating was initiated by H.C. Wainwright with “Buy” on Tuesday, September 8. The firm earned “Buy” rating on Wednesday, March 30 by H.C. Wainwright. Piper Jaffray maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Tuesday, July 25. Piper Jaffray has “Buy” rating and $1200 target.

Since August 21, 2017, it had 0 insider purchases, and 1 sale for $410,000 activity. Another trade for 20,000 shares valued at $410,000 was made by Johnson Ellen Tobi on Monday, August 21.

Investors sentiment increased to 1.19 in 2017 Q3. Its up 0.19, from 1 in 2017Q2. It increased, as 58 investors sold IPG shares while 129 reduced holdings. 64 funds opened positions while 159 raised stakes. 382.86 million shares or 1.99% more from 375.40 million shares in 2017Q2 were reported. Westpac Bk Corporation holds 0.01% or 23,686 shares. Ontario Teachers Pension Plan Board holds 201,896 shares or 0.06% of its portfolio. Conning holds 9,926 shares or 0.01% of its portfolio. Hl Fin Svcs Ltd Liability Corp accumulated 0.01% or 35,128 shares. Freestone Capital Ltd invested in 955,675 shares. First Republic Inv Mgmt Inc invested 0.01% in The Interpublic Group of Companies, Inc. (NYSE:IPG). Martin Currie Ltd holds 0.41% or 258,500 shares. British Columbia Inv Mgmt has invested 0.03% of its portfolio in The Interpublic Group of Companies, Inc. (NYSE:IPG). Td Asset Management Inc has 0% invested in The Interpublic Group of Companies, Inc. (NYSE:IPG). State Of Alaska Department Of Revenue invested 0.05% in The Interpublic Group of Companies, Inc. (NYSE:IPG). Royal Financial Bank Of Canada invested in 0.01% or 727,864 shares. Oakworth Cap Inc, Alabama-based fund reported 205 shares. River Road Asset Mngmt Ltd Com invested 1.32% of its portfolio in The Interpublic Group of Companies, Inc. (NYSE:IPG). 93,110 are held by Oppenheimer Asset. Alpha Windward Ltd Limited Liability Company holds 0.02% or 1,414 shares.

Pioneer Investment Management Inc decreased Hanover Insurance Group In (NYSE:THG) stake by 126,629 shares to 295,676 valued at $28.66M in 2017Q3. It also reduced Goodyear Tire & Rubber Com (NASDAQ:GT) stake by 51,190 shares and now owns 1.59 million shares. Goldman Sachs Group Inc/Th (NYSE:GS) was reduced too.

Among 17 analysts covering Interpublic Group of Companies (NYSE:IPG), 11 have Buy rating, 2 Sell and 4 Hold. Therefore 65% are positive. Interpublic Group of Companies had 45 analyst reports since September 7, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Monday, April 24 by Telsey Advisory Group. Telsey Advisory Group maintained The Interpublic Group of Companies, Inc. (NYSE:IPG) rating on Thursday, October 22. Telsey Advisory Group has “Outperform” rating and $27.50 target. RBC Capital Markets maintained the shares of IPG in report on Friday, January 6 with “Top Pick” rating. The firm has “Buy” rating by RBC Capital Markets given on Monday, June 12. The firm has “Hold” rating given on Monday, August 28 by RBC Capital Markets. BMO Capital Markets maintained The Interpublic Group of Companies, Inc. (NYSE:IPG) rating on Monday, October 16. BMO Capital Markets has “Buy” rating and $26.0 target. The firm has “Buy” rating given on Tuesday, May 23 by Jefferies. Zacks upgraded the shares of IPG in report on Monday, September 7 to “Buy” rating. The firm has “Hold” rating by RBC Capital Markets given on Friday, September 29. As per Wednesday, October 21, the company rating was maintained by Pivotal Research.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *